OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards

Oxford, UK - 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the CDMO Leadership Awards in New York City.

You will be redirected in 10 seconds.

liveinternet liveinternet